# Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

> **NCT04580745** · PHASE1 · COMPLETED · sponsor: **Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)** · enrollment: 67 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MORF-057
- **DRUG:** Placebo for MORF-057

## Key facts

- **NCT ID:** NCT04580745
- **Lead sponsor:** Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-04-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580745, "Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04580745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*